Patent: 9,314,460
✉ Email this page to a colleague
Summary for Patent: 9,314,460
Title: | Method for cancer cell reprogramming |
Abstract: | In one embodiment, the invention provides a method of inhibiting cAMP efflux and increasing intracellular cAMP in a subject who suffers from, or who is at risk of developing, a cancer by administering to the subject a therapeutically-effective amount of a cAMP efflux inhibitor. Novel compounds, pharmaceutical compositions, diagnostics and screening methods are also provided. |
Inventor(s): | Chigaev; Alexandre (Santa Fe, NM), Sklar; Larry A. (Albuquerque, NM), Perez; Dominique (Albuquerque, NM) |
Assignee: | STC.UNM (Albuquerque, NM) |
Application Number: | 14/249,150 |
Patent Claims: | see list of patent claims |
Details for Patent 9,314,460
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2033-04-09 |
Merck Teknika Llc | TICE BCG | bcg live | For Injection | 102821 | 06/21/1989 | ⤷ Try a Trial | 2033-04-09 |
Merck Teknika Llc | N/A | bcg vaccine | For Injection | 103050 | 06/21/1989 | ⤷ Try a Trial | 2033-04-09 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | 06/04/1986 | ⤷ Try a Trial | 2033-04-09 |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | For Injection | 103132 | ⤷ Try a Trial | 2033-04-09 | |
Merck Sharp & Dohme Corp. | INTRON A | interferon alfa-2b | Injection | 103132 | ⤷ Try a Trial | 2033-04-09 | |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |